Vito Franco

ORCID: 0000-0003-3231-1367
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Acute Myeloid Leukemia Research
  • Kruppel-like factors research
  • Chronic Myeloid Leukemia Treatments
  • Phagocytosis and Immune Regulation
  • Eosinophilic Disorders and Syndromes
  • Calcium signaling and nucleotide metabolism
  • Acute Lymphoblastic Leukemia research
  • HER2/EGFR in Cancer Research
  • Multiple Myeloma Research and Treatments
  • Hematological disorders and diagnostics
  • Glycosylation and Glycoproteins Research
  • Monoclonal and Polyclonal Antibodies Research
  • Vascular Malformations and Hemangiomas
  • Multiple and Secondary Primary Cancers
  • Breast Cancer Treatment Studies
  • Platelet Disorders and Treatments
  • T-cell and Retrovirus Studies
  • Vascular Tumors and Angiosarcomas
  • Hepatitis C virus research
  • Peptidase Inhibition and Analysis

University of Palermo
2007-2019

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo
2006-2014

University of Palermo
2005

Indiana University – Purdue University Indianapolis
2005

Istituto di Ematologia di Bologna
2004

University of Bologna
2004

University of Verona
2004

Instituto Nacional do Câncer
2004

Institute of Normal and Pathological Physiology of the Slovak Academy of Sciences
1999

Cornell University
1995

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult previously untreated stages II IV FL compare efficacy of eight doses R cycles cyclophosphamide, vincristine, prednisone (CVP) or six doxorubicin, (CHOP) fludarabine mitoxantrone (FM). The principal end point study...

10.1200/jco.2012.45.0866 article EN Journal of Clinical Oncology 2013-03-26

Abstract Objective Subclinical gut inflammation is common in spondylarthritis, but the immunologic abnormalities underlying this process are undefined. Perturbation of interleukin‐23 (IL‐23)/Th17 axis has emerged as a fundamental trigger chronic inflammation. This study was undertaken to investigate expression and tissue distribution IL‐23/Th17–related molecules Crohn's disease (CD) subclinical ankylosing spondylitis (AS). Methods Quantitative gene analysis Th1/Th2 IL‐23/Th17 responses...

10.1002/art.24389 article EN Arthritis & Rheumatism 2009-03-30

CD38 and CD49d are associated negative prognosticators in chronic lymphocytic leukemia (CLL). Despite evidence that both molecules involved interactions occurring between CLL normal cells the context of CLL-involved tissues, a functional link is still missing. Using gene expression profiles comparing CD38(+)CD49d(+) versus CD38(-)CD49d(-) cells, we showed overexpression CCL3 CCL4 chemokines from former group. These were also up-regulated by signals CLL; moreover, was expressed bone marrow...

10.1158/0008-5472.can-08-4173 article EN Cancer Research 2009-04-22

A particular type of lymphomatous bone marrow infiltration defined as intrasinusoidal and occuring in seven patients with splenomegaly mild to moderate thrombocytopenia is reported. Immunocytochemistry highlighted the pattern showed a mature B‐cell phenotype. Four underwent splenectomy diagnosis splenic marginal cell lymphoma was made. The disease course seems be chronic quite indolent. All are alive well; follow‐up ranges from 2 42 months. value biopsy primary diagnostic tool zone lymphomas...

10.1046/j.1365-2559.1996.d01-536.x article EN Histopathology 1996-12-01

Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, minimal diagnostic data set, and therapy remain unanswered.Clinical-pathologic features outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly were diagnosed SMZL or without (+/-) villous lymphocytes (VL) reviewed.SMVL +/- VL occurred mostly in elderly males (median age, 62 years 10 years; male-to-female...

10.1002/cncr.20596 article EN Cancer 2004-09-23

We reviewed a large series of patients with essential thrombocythemia diagnosed on the basis Polycythemia Vera Study Group criteria, and reclassified them by evaluating their major morphologic features clinical course using World Health Organization classification. The review bone marrow biopsies 116 (44 males 72 females; aged 19 – 83 years, median 55 years; follow-up 121 months) led to 22 cases (19%) being classified as (ET), 24 (21%) chronic idiopathic myelofibrosis (CIMF)-0, 44 (37%)...

10.1080/10428190600678975 article EN Leukemia & lymphoma/Leukemia and lymphoma 2006-01-01

BACKGROUND Splenic marginal zone cell lymphoma (SMZL) is a low grade B-cell in which patients can have circulating villous lymphocytes and show peculiar intrasinusoidal bone marrow (BM) infiltration. Splenectomy the reported treatment of choice for these patients. The objective this study was to evaluate effects splenectomy on with BM lymphomatous METHODS biopsies 16 SMZL were studied morphologically immunohistochemically. In 12 patients, taken before after splenectomy. Four did not undergo...

10.1002/1097-0142(20010115)91:2<294::aid-cncr1001>3.0.co;2-w article EN Cancer 2001-01-01

Abstract: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was assess the frequency LS, its relationship host viral factors extent can influence combination therapy pegylated interferon (INF)+ribavirin in group patients CHC from single center. Patients: One...

10.1111/j.1478-3231.2006.01347.x article EN Liver International 2006-10-10

According to the ToGA trial, HER2 has been shown be predictive for success of treatment with trastuzumab in advanced gastric cancer (AGC). A number studies have analyzed HER‑2/neu overexpression carcinoma and identified rate positivity markedly varied. To date, prevalence Sicilian people AGC is unknown. Therefore, present study, a retrospective immunohistochemical analysis was performed cohort 304 samples that were obtained from archives 10 anatomopathological diagnostic units order verify...

10.3892/ol.2013.1611 article EN Oncology Letters 2013-10-10

Human epidermal growth factor receptor 2 (HER2) is considered to be a therapeutic and prognostic marker in the management of breast carcinoma (BC), although discordance rates between primary metastatic or locally recurrent lesions have been reported.One hundred forty-eight paraffin-embedded BC tissues from patients mean age 59.27 (33-96) years corresponding synchronous lymph node metastases were collected retrospectively studied using immunohistochemistry fluorescence situ hybridization...

10.2147/ott.s65294 article EN cc-by-nc OncoTargets and Therapy 2014-07-01

10.1016/s0344-0338(11)80297-9 article EN Pathology - Research and Practice 1990-06-01

A Symposium regarding the Pathophysiology of Successful and Unsuccessful Ageing was held in Palermo, Italy on 7-8 April 2009. Three lectures from that by G. Campisi, L. Ginaldi F. Licastro are here summarized. is a complex process which negatively impacts development various bodily systems its ability to function. long life healthy, vigorous, youthful body has always been one humanity's greatest dreams. Thus, better understanding pathophysiology age-related diseases urgently required improve...

10.1186/1742-4933-6-12 article EN cc-by Immunity & Ageing 2009-09-08

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial SMZL who were either untreated or splenectomized but had shown progression within 1 year after splenectomy. Treatment consisted of six courses cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin prednisone (R-COMP). Fifty-one eligible for the analysis. The overall rate was 84%. 6-year progression-free survival 54% 72%,...

10.3109/10428194.2015.1029925 article EN Leukemia & lymphoma/Leukemia and lymphoma 2015-03-20

&lt;i&gt;Objective:&lt;/i&gt; We aimed to investigate the existence of associations between well-established and newly recognized biological phenotypic features breast cancer involved in tumor progression prognosis. &lt;i&gt;Methods:&lt;/i&gt; Ninety-eight cases invasive were assessed for immunohistochemical expression estrogen progesterone receptors, Ki-67, HER2, Akt-1, Notch-2, using tissue microarray technique. Data regarding histotype, histological grade, size lymph node status collected...

10.1159/000110024 article EN Pathobiology 2007-01-01
Coming Soon ...